Abstract |
Twenty-five women with advanced breast cancer were treated in a phase II trial of iproplatin 275 mg/m2 administered intravenously every 4 weeks. All patients had measurable or evaluable indicator lesions, and had undergone treatment with no more than one previous chemotherapy regimen, including adjuvant chemotherapy. Two of the twenty-four evaluable patients (8%) experienced major therapeutic responses. One patient had a complete regression of pulmonary nodules lasting 18+ months; another had a partial regression of metastatic disease in the liver (4 months). The inevaluable patient was ineligible for the study because of previous radiation to the indicator lesions on her chest wall; nonetheless, she experienced a 10 month partial regression of those nodules. Myelosuppression was generally dose limiting; thrombocytopenia was more profound, but leukopenia was more prolonged. Nausea, vomiting, diarrhea, and general malaise were prominent toxicities, and led to discontinuation of therapy in 4 patients. Iproplatin has limited activity in previously treated women with advanced breast cancer.
|
Authors | E S Casper, T C Smart, T B Hakes, M Ochoa Jr, R J Kaufman |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 6
Issue 2
Pg. 87-91
(Jun 1988)
ISSN: 0167-6997 [Print] United States |
PMID | 3049433
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- iproplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Bone Marrow
(drug effects)
- Breast Neoplasms
(drug therapy)
- Clinical Trials as Topic
- Female
- Humans
- Middle Aged
- Organoplatinum Compounds
(adverse effects, therapeutic use)
|